8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):  February 8, 2011

UNIVERSAL AMERICAN CORP.

(Exact Name of Registrant as Specified in Its Charter)

New York
(State or Other Jurisdiction
of Incorporation) 0-11321
(Commission File Number) 11-2580136
(I.R.S. Employer Identification
No.)

Six International Drive, Suite 190

Rye Brook, New York 10573

(Address of principal executive offices) (Zip Code)

(914) 934-5200

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

xWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.             Other Events.

On February 8, 2011, Richard Barasch, Chairman and CEO of Universal American Corp. (the “Company”) gave a presentation at the UBS 21st Annual Global Healthcare Services Conference in New York City.  A copy of the presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Forward Looking Statements

This Current Report on Form 8-K (including information included or incorporated by reference herein) contains “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA.  Such statements that are not historical facts are hereby identified as forward-looking statements and intended to be covered by the safe harbor provisions of the PSLRA and can be identified by the use of the words “believe,” “expect,” “predict,” “project,” “potential,” “estimate,” “anticipate,” “should,” “intend,” “may,” “will,” and similar expressions or variations of such words, or by discussion of future financial results and events, strategy or risks and uncertainties, trends and conditions in the Company’s business and competitive strengths, all of which involve risks and uncertainties.

Where, in any forward-looking statement, the Company or its management expresses an expectation or belief as to future results or actions, there can be no assurance that the statement of expectation or belief will result or be achieved or accomplished.  The Company’s actual results may differ materially from its expectations, plans or projections.  The Company warns you that forward-looking statements are only predictions and estimates, which are inherently subject to risks, trends and uncertainties, many of which are beyond the Company’s ability to control or predict with accuracy and some of which it might not even anticipate.  These risks and uncertainties include:  the timing to consummate the Company’s proposed transaction with CVS Caremark Corporation; negative effects from the pendency of the transaction; the risk that a condition to closing of the proposed transaction may not be satisfied; the risk that a regulatory approval that may be required for the proposed transaction is not obtained or is obtained subject to conditions that are not anticipated; the ability of the Company to timely receive the required approval of its shareholders; the risk that the contemplated transaction does not occur for any other reason; the possibility that costs or difficulties related to the separation of the Medicare Prescription Drug Business will be greater than expected; the risks to “NewCo,” the newly formed public company that will be distributed to the Company’s shareholders as part of the CVS Caremark transaction, on its ability to effectively operate its businesses independently of the Medicare Prescription Drug Business, including its ability to access sufficient sources of capital to fund its operations; the risks to NewCo’s ability to retain and hire key personnel; the diversion of management time on transaction-related issues and other risks described in the risk factor section of the Company’s SEC reports.  The Company gives no assurance that it will achieve its expectations and it does not assume responsibility for the accuracy and completeness of the forward-looking statements.  Future events and actual results, financial and otherwise, may differ materially from the results discussed in the forward-looking statements as a result of many factors, including the risk factors described in the risk factor section of its SEC reports.  The Company cautions readers not to place undue reliance on these forward-looking statements that speak only as of the date made. All forward-looking statements included in this Current Report on Form 8-K (including information included or incorporated by reference herein) are based upon information available to the Company as of the date hereof, and the Company assumes no obligation to update or revise any such forward-looking statements.

Additional Information

In connection with the proposed transaction, NewCo will file with the SEC a Registration Statement on Form S-4 that will include a proxy statement of the Company that also constitutes a prospectus of NewCo.  The Company will mail the proxy statement/prospectus to its shareholders. BEFORE MAKING ANY VOTING DECISION, SHAREHOLDERS OF THE COMPANY ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS CAREFULLY BECAUSE THE PROXY STATEMENT/PROSPECTUS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.  You may obtain copies of all documents filed with the SEC regarding this transaction, free of charge, at the SEC’s website (sec.gov).  You will also be able to obtain these documents, free of charge, when filed, from the Company’s website, www.UniversalAmerican.com, under the tab “Investors” and then under the tab “SEC Filings.”

2

The Company and its directors, executive officers and certain other members of management and employees may be soliciting proxies from the Company shareholders in favor of the merger and the separation.  Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the Company shareholders in connection with the proposed transaction will be set forth in the proxy statement/prospectus when it is filed with the SEC.  You can find information about the Company’s executive officers and directors in its definitive proxy statement filed with the SEC on April 30, 2010.

Item 9.01.             Financial Statements and Exhibits.

(d) Exhibits.

99.1      Presentation dated February 8, 2011

3

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 8, 2011

UNIVERSAL AMERICAN CORP.
By:	/s/ Tony L. Wolk
	Name: Tony L. Wolk
	Title: SVP, General Counsel and Secretary

4

EXHIBIT INDEX

99.1      Presentation dated February 8, 2011

5

EX-99.1

Exhibit 99.1

UBS Healthcare Conference February 8, 2011

Forward-Looking Statements/Non-GAAP Financial Measures This presentation contains "forward-looking" statements within the meaning of the federal securities laws. We warn you that forward-looking statements are only predictions and estimates, which are inherently subject to risks, trends and uncertainties, many of which are beyond our ability to control or predict with accuracy and some of which we might not even anticipate. These risks and uncertainties include: the timing to consummate the proposed transaction with CVS Caremark; negative effects from the pendency of the transaction; the risk that a condition to closing of the proposed transaction may not be satisfied; the risk that a regulatory approval that may be required for the proposed transaction is not obtained or is obtained subject to conditions that are not anticipated; the ability of Universal American to timely receive the required approval of its shareholders; the risk that the contemplated transaction does not occur for any other reason; the possibility that costs or difficulties 2 related to the separation of the Medicare Prescription Drug Business will be greater than expected; the risks to NewCo's ability to effectively operate its businesses independently of the Medicare Prescription Drug Business, including its ability to access sufficient sources of capital to fund its operations; the risks to NewCo's ability to retain and hire key personnel; the diversion of management time on transaction-related issues and other risks described in the risk factor section of our SEC reports. We give no assurance that we will achieve our expectations and we do not assume responsibility for the accuracy and completeness of the forward-looking statements. All forward-looking statements included in this presentation are based upon information available to Universal American as of the date of the presentation, and we assume no obligation to update or revise any such forward-looking statements. The discussion in this presentation of Universal American’s financial performance includes financial measures that are not derived from generally accepted accounting principles, or GAAP. Information regarding these non-GAAP financial measures is available in our quarterly earnings press releases in the Investor Relations section of Universal American’s website at www.universalamerican.com.

Additional Information In connection with the proposed transaction with CVS Caremark, NewCo will file with the SEC a Registration Statement on Form S-4 that will include a proxy statement of Universal American that also constitutes a prospectus of NewCo. We will mail the proxy statement/prospectus to our shareholders. BEFORE MAKING ANY VOTING DECISION, SHAREHOLDERS OF UNIVERSAL AMERICAN ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS CAREFULLY BECAUSE THE PROXY STATEMENT/PROSPECTUS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. 3 You may obtain copies of all documents filed with the SEC regarding this transaction, free of charge, at the SEC’s website (sec.gov). You will also be able to obtain these documents, free of charge, when filed, from our website, www.UniversalAmerican.com, under the tab “Investors” and then under the tab “SEC Filings.” Universal American and its directors, executive officers and certain other members of our management and employees may be soliciting proxies from Universal American shareholders in favor of the merger and the separation. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of Universal American shareholders in connection with the proposed transaction will be set forth in the proxy statement/prospectus when it is filed with the SEC. You can find information about Universal American’s executive officers and directors in its definitive proxy statement filed with the SEC on April 30, 2010.

Senior Market: It’s only just beginning... 50 55 60 65 $700 $900 $1,100 Population Spending 4 40 45 $300 $500 '10 '11 '12 '13 '14 '15 '16 '17 '18 '19 '20 Spending ($ billions) Population (millions) Fastest growing demographic segment. Baby boomers started to reach 65 in 2010. Source: CMS website and 2009 Board of Trustees Report.

Universal American Evolution 2004 2005 2006 2007 2008 2009 2010 ($ in millions) Actual Actual Actual Actual Actual Actual Guidance Revenues Medicare Advantage $94 13% $241 0% $451 33% $1,943 62% $2,421 51% $2,643 53% $3,150 56% Medicare Part D - 0% 0 0% 294 22% 643 21% 1,896 40% 1,984 40% 2,188 39% Traditional Insurance 620 85% 669 96% 577 43% 515 16% 456 10% 346 7% 305 6% Other (1) 12 2% 20 4% 25 2% 30 1% 18 0% 16 0% 7 0% Total Revenues (2) $726 100% $932 100% $1,349 100% $3,130 100% $4,790 100% $4,989 100% $5,649 100% 5 Part D Rollout Acquired Member-Health PFFS Expansion Key Developments PPO Rollout MIPPA Legislation Changed Regulatory and Political Environment Passage of Healthcare Reform Notes: (1) Other reflects Senior Administrative Services, Corporate, and eliminations (2) Total Revenue excludes Realized Gains/(Losses) Sold L&A to GWA Paid $2.00 Special Dividend Acquired Heritage

2010 Highlights Medicare Advantage Net membership growth of 39K, or 20% Successful network filings for Network PFFS/PPO Strong financial performance BUT... CMS sanctions Part D Net membership growth of 200K, or 11.9% 6 Improved financial/operating performance Announced sale to CVS Traditional New Med Supp plans filed in 42 states, 30 with fresh start pricing Rate increases filed and approved Improved operating expenses run-rate Balance Sheet/Capital Management Paid $2.00 special cash dividend Significant investment portfolio rebalancing

Medicare Part D Highlights Membership 3rd largest Part D Plan and LIS Part D Plan by membership –1.9 mm members as of Jan. 2011 –1.4 mm LIS members as of Jan. 2011 Plan Consolidation for 2011 – From 5 to 2 = only CCRx Basic & CCRx 7 Revenues ** Reflects midpoint of guidance Choice (Enhanced) 2011 Bid Results –Below benchmark in 26 regions –De minimis in 3 regions –Loss of 1 existing region (NV = 5k members) –No AEP one-time auto-assigned duals on January 1, 2011; monthlies restarted Lipitor/Crestor in Tier 1 formulary *2008 Pro Forma membership reflects dissolution of CVS Partnership

Part D Market Position Company Membership (000’s) 1 United Health Group 4,576 2 Humana 2,039 3 Universal American 1,885 4 CVS Caremark 1,553 8 5 Coventry 1,293 6 WellCare 916 7 HealthSpring 828 8 Medco 707 9 WellPoint 634 10 Aetna 538 Membership as of January 2011 CMS Report

CVS Caremark Transaction Highlights Strategic Considerations –Attractive valuation; all cash proceeds –Focus on overcoming near-term regulatory challenges and rebuilding momentum in the Medicare Advantage business Transaction Structure On December 31, 2010, Universal American and CVS Caremark announced a definitive agreement under which CVS will acquire the Part D business of Universal American. CVS Caremark will acquire all of the stock of Universal American and concurrently distribute to Universal American shareholders 100% of the shares of a newly formed public company 9 Tax Implications –Cash and FMV of the NewCo stock at closing will be taxable proceeds to shareholders Closing expected by the end of 2Q ‘11 –HSR review –State Insurance Department approvals –Shareholder approval (“NewCo”), which will own all other operations of Universal American, including its Medicare Advantage and Traditional Insurance businesses. CVS Caremark will pay Universal American shareholders $1.25 billion plus the excess capital in the Part D entities as of 12/31/10, estimated at $150 million, less Universal American’s outstanding debt and trust preferred securities, estimated at $340 million. After transaction expenses, Universal American shareholders are expected to receive approximately $12.80-13.00 per share in cash, plus one share of NewCo.

NewCo Medicare Advantage: Healthy Collaboration – HMO – PPO – NPFFS – Rural PFFS 10 Traditional Insurance – Medicare Supplement, etc All Statutory Entities, except Pennsylvania Life – Approx. $640 mm of cash and SAP capital as of 12/31/2010 Same management team Challenge: resize G&A expenses by closing date

Medicare Advantage 2010 Highlights Membership 2011 Marketing Suspension Healthy CollaborationSM model -Investment in Medical Management Network Coverage – 55 markets 241,000 240,000 290,000 11 Revenue *Reflects 2010 Guidance. Membership excludes commercial – Focus on Network PFFS Rural Strategy Focus on Star rating: –Average of 3 out of 5 stars

 On November 19th 2010, CMS notified the Company of the imposition of intermediate sanctions – Effective December 5th 2010, marketing and enrollment of new members was suspended in Medicare Advantage plans The suspension relates primarily to agent oversight and market conduct issues Impact on current membership CMS Sanctions 12 – Current Medicare Advantage members – No impact – Part D members – No impact – Lapsation Working diligently with CMS No timeframe for lifting the sanction

Estimated January 2011 MA Membership Estimated Membership (000's) HMO 63 PPO 24 Rural PFFS 33 Non-Rural PFFS 57 Total PFFS 91 13 Total Medicare Advantage 178

MA Reimbursement After 2011 – Estimated UAM Membership Distribution Target Benchmark / FFS Cost Ratio Transition Period 95.0% 100.0% 107.5% 115.0% Total 2 year 1% 2% 4% 10% 17% 4 year 3% 5% 6% 15% 29% 14 Based on estimated January membership. 6 year 34% 3% 5% 12% 54% Total 38% 10% 15% 37% 100% HMO 95% 4% 1% 0% 100% PPO 12% 12% 17% 58% 100% PFS-Non Rural 7% 9% 19% 65% 100% PFS-Rural 17% 18% 27% 38% 100% Total MA 38% 10% 15% 37% 100%